Sanofi
Q3 2025 13F Holdings
- Locationparis, I0
- Num holdings
9
- Value ($000)
$260,361
- Date Filed11/04/2025
- Form type13F-HR
- CIK0001121404
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
MeiraGTx Holdings plc | COM | G59665102 | $100.39 M | 39 % | 12,197,737 | ||
NVV1 Novavax | COM NEW | 670002401 | $59.65 M | 23 % | 6,880,481 | ||
INBX Inhibrx Biosciences, Inc. | COM | 45720N103 | $39.00 M | 15 % | 1,157,926 | ||
ANAB AnaptysBio | COM | 032724106 | $25.17 M | 10 % | 821,917 | ||
IMRX Immuneering Corp | CLASS A COM | 45254E107 | $18.96 M | 7 % | 2,708,559 | ||
Omada Health Inc. | COM | 68170A108 | $11.61 M | 5 % | 524,903 | ||
LAVA Therapeutics N.V. | SHS | N51517105 | $2.99 M | 1 % | 1,919,455 | ||
ELDN Eledon | COM | 28617K101 | $2.11 M | 1 % | 814,980 | ||
QTTB Q32 Bio Inc. | COM | 746964105 | $483.28 K | 0 % | 244,083 |
Rows Per Page
10
- 10
- 50
- 100